Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Emisphere -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (188)	11/9/2002 12:13:48 AM
From: hmpa	Read Replies (1) \| Respond to of 272

<<Actually, it was big mistake to do PIII in first place>> Science wise, yes. Business wise, start of "any" Phase III in early 2000 was a tremendous boost to stock price, and was a key factor which allowed them to get some $200MM of investors' money in 03/2000. Even after they blew 1/3 of this on a weak trial, and another 1/3 on running the company for 2.5 years, the money left will allow them to be in shape financially till at least the end of 2005. I think the Lilly partnered programs alone should provide a many xx stock price increase. LLY had a nice cc today, talking about Forteo injection launch in early 2003. However, the only chance for Forteo to survive the onslaught of other PTH products (primarily, one from NPSP) will be to "oralise" the drug, and they have a strong driver to push this EMIS program ahead as fast as possible. Ditto for rHGH.